arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

download Export Data

Mereo BioPharma Group plc

MREO

$0.31 ▲ +0.02 (+7.24%) at close

16 Visible periods

25 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Mereo BioPharma Group plc faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $249.1M

Dividend Yield —

Revenue Growth —

Op. Margin None

ROIC -24.5% ↗

FCF / Share $-0.01 ↘

Trailing P/E —

Price / Book 8.7x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Sep 22, 2026.

16-Year Financial Trajectory

Quarterly

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$0.00

— —

Net Income Profit after all expenses

$-6.72M

↑ +47.9% —

FCF / Share Free cash flow per share

$-0.01

↑ +21.4% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓

Financial Health ↓

Cash Quality ↓

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	Q2 FY2026 Jun 30, 2026 10-Q ↗	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q4 FY2021 Dec 31, 2021 10-K ↗
EPS Growth YoY (%)	50.0% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	50.0% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	-0.0% Weak ↑ Weak Improving Year-over-year change in earnings per share Optimal: > 10%	50.0% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	0.0% Caution ↑ Caution Improving Year-over-year change in earnings per share Optimal: > 10%	-100.0% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	0.0% Caution ↑ Caution Improving Year-over-year change in earnings per share Optimal: > 10%	-100.0% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	—	50.0% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—	—	—
Net Income Growth YoY (%)	47.9% Excellent ↑ Excellent Improving Year-over-year change in net income	47.9% Excellent ↑ Excellent Improving Year-over-year change in net income	-4.3% Weak ↑ Weak Improving Year-over-year change in net income	-44.0% Weak ↓ Weak Declining Year-over-year change in net income	-44.0% Weak ↓ Weak Declining Year-over-year change in net income	-44.0% Weak ↓ Weak Declining Year-over-year change in net income	22.6% Good ↓ Good Declining Year-over-year change in net income	25.9% Excellent → Excellent Stable Year-over-year change in net income	25.9% Excellent Excellent Year-over-year change in net income	25.9% Excellent Excellent Year-over-year change in net income	—	—	—	—	—	—
FCF Growth YoY (%)	21.4% Good Good Year-over-year change in free cash flow	49.5% Excellent Excellent Year-over-year change in free cash flow	—	—	—	6.7% Fair Fair Year-over-year change in free cash flow	—	—	—	23.0% Good Good Year-over-year change in free cash flow	—	—	—	—	—	—

💰 Are margins durable? 5 metrics

Metric	Q2 FY2026 Jun 30, 2026 10-Q ↗	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q4 FY2021 Dec 31, 2021 10-K ↗
Operating Margin (%) (%)	—	—	—	—	—	—	—	—	—	—	—	—	-9.0% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-160%)	—	—	—
Effective Tax Rate (%) (%)	0.0% Excellent → Excellent Stable Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent → Excellent Stable Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent → Excellent Stable Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent → Excellent Stable Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent → Excellent Stable Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent → Excellent Stable Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent → Excellent Stable Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	5.5% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent → Excellent Stable Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	—
Profit Margin (%) (%)	—	—	—	—	—	—	—	—	—	—	—	—	-134.2% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1218%)	—	—	—
FCF Margin (%) (%)	—	—	—	—	—	—	—	—	—	—	—	—	-86.2% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	—	—	—
FCF / Net Income (x)	0.90x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.64x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	1.05x Fair ↑ Fair Improving Free cash flow relative to reported net income Optimal: > 1x	0.57x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.59x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.65x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	1.34x Good Good Free cash flow relative to reported net income Optimal: > 1x	—	—	0.89x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.75x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	-0.22x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.64x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	0.77x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—	—

🎯 Is capital allocation efficient? 3 metrics

Metric	Q2 FY2026 Jun 30, 2026 10-Q ↗	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q4 FY2021 Dec 31, 2021 10-K ↗
Return on Invested Capital (%)	-24.5% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-25.7% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-20.5% Weak → Weak Stable Return earned on debt + equity capital invested Optimal: > 10%	-21.5% Weak → Weak Stable Return earned on debt + equity capital invested Optimal: > 10%	-19.4% Weak → Weak Stable Return earned on debt + equity capital invested Optimal: > 10%	-18.6% Weak → Weak Stable Return earned on debt + equity capital invested Optimal: > 10%	-25.1% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-12.9% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-16.3% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-23.1% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-13.3% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-16.6% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-1.6% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	-25.7% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	—	—
Return on Capital (%) (%)	-20.3% Weak → Weak Stable Operating profit relative to total assets Optimal: > 10%	-21.6% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-18.3% Weak → Weak Stable Operating profit relative to total assets Optimal: > 10%	-18.7% Weak → Weak Stable Operating profit relative to total assets Optimal: > 10%	—	-16.4% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-20.0% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-10.6% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-13.3% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-17.7% Weak Weak Operating profit relative to total assets Optimal: > 10%	-10.7% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—	—	—	—
Return on Common Equity (%) (%)	-23.5% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-256%)	-19.7% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-232%)	-18.0% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-220%)	-27.7% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-284%)	-23.8% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-259%)	-21.4% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-243%)	-11.6% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-177%)	-12.3% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-182%)	-11.4% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-176%)	-20.9% Weak → Weak Stable Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-239%)	-18.0% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-220%)	-22.1% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-247%)	-24.3% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-262%)	-27.2% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-281%)	—	—

⚖️ Is the balance sheet risky? 2 metrics

Metric	Q2 FY2026 Jun 30, 2026 10-Q ↗	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q4 FY2021 Dec 31, 2021 10-K ↗
Interest Coverage (x)	-439.38x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-438.30x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-364.78x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-357.68x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-437.46x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-62.23x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-40.73x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-26.55x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-38.71x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-31.94x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-20.19x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-12.95x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-0.79x Weak Weak Operating income divided by interest expense Optimal: > 5x	-14.26x Weak Weak Operating income divided by interest expense Optimal: > 5x	—	—
Net Debt (USD)	$-30.12M	$-36.22M	$-40.99M	$-48.70M	—	$-62.48M	$-69.80M	$-80.52M	$-87.43M	$-48.66M	$-57.42M	—	—	—	$-68.18M	—

📊 What does each share earn? 6 metrics

Metric	Q2 FY2026 Jun 30, 2026 10-Q ↗	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q4 FY2021 Dec 31, 2021 10-K ↗
Revenue per Share (USD)	$0.00	—	—	$0.00	$0.00	—	—	$0.00	$0.00	$0.00	—	$0.00	$0.01	$0.00	—	—
Basic EPS, GAAP (USD)	$-0.01	$-0.01	$-0.01	$-0.01	$-0.02	$-0.02	$-0.01	$-0.02	$-0.02	$-0.01	$-0.01	$-0.01	$0.00	$-0.02	—	—
Free Cash Flow per Share (USD)	$-0.01	$-0.01	—	$-0.01	$-0.01	$-0.01	—	—	—	$-0.01	—	$0.00	$-0.01	$-0.01	—	—
Book Value per Share (USD)	$0.04	$0.04	—	$0.06	$0.07	$0.08	—	$0.09	$0.11	$0.06	—	$0.08	$0.08	$0.07	—	—
Tangible Book Value per Share (USD)	$0.04	$0.04	—	$0.06	$0.07	$0.08	—	$0.09	$0.11	$0.06	—	$0.08	$0.08	$0.07	—	—
Basic Weighted Avg Shares (shares)	803.56M	801.81M	—	799.95M	799.44M	784.28M	—	770.15M	711.77M	700.26M	—	684.97M	628.42M	623.93M	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	Q2 FY2026 Jun 30, 2026 10-Q ↗	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q4 FY2021 Dec 31, 2021 10-K ↗
Working Capital (USD)	$27.72M	$33.86M	$40.72M	$46.39M	—	$59.40M	$60.91M	$72.52M	$78.47M	$42.49M	$54.27M	—	—	—	$50.82M	—
Total Equity (USD)	$28.65M	$34.05M	$40.92M	$46.60M	$54.18M	$60.08M	$60.97M	$72.54M	$78.65M	$42.84M	$50.54M	$54.71M	$49.66M	$44.40M	$51.40M	$92.20M

📋 What is driving earnings? 4 metrics

Metric	Q2 FY2026 Jun 30, 2026 10-Q ↗	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q4 FY2021 Dec 31, 2021 10-K ↗
Sales/Revenue/Turnover (USD)	$0.00	—	$0.00	$0.00	$500.00K	—	$0.00	$0.00	$0.00	$0.00	$1.00M	$0.00	$9.00M	$0.00	—	—
Depreciation Expense (USD)	$38.00K	$44.00K	$36.00K	$39.00K	$44.00K	$38.00K	$38.00K	$100.00K	$100.00K	$41.00K	$42.00K	$100.00K	$100.00K	$42.00K	—	—
Net Income, GAAP (USD)	$-6.72M	$-6.72M	$-7.35M	$-12.89M	$-12.89M	$-12.89M	$-7.05M	$-8.95M	$-8.95M	$-8.95M	$-9.11M	$-12.08M	$-12.08M	$-12.08M	—	—
Operating Cash Flow (USD)	$-6.04M	$-4.31M	$-7.68M	$-7.31M	$-7.65M	$-8.33M	$-9.42M	—	—	$-7.99M	$-6.79M	$2.66M	$-7.75M	$-9.25M	—	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 5 years · 16 quarters

Mereo BioPharma Group plc

Analytical Summary

16-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare MREO with peers